| Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival MG Abdelmagid, A Al-Kali, KH Begna, WJ Hogan, MR Litzow, F Fleti, ... Haematologica 108 (9), 2542, 2023 | 3 | 2023 |
| TP53 mutations and variant allele frequency in myelodysplastic syndromes with del (5q): A Mayo-Moffitt study of 156 informative cases F Fleti, O Chan, A Singh, MG Abdelmagid, A Al-Kali, MA Elliott, KH Begna, ... American journal of hematology 98 (4), E76-E79, 2023 | 3 | 2023 |
| Lenalidomide therapy for primary myelodysplastic syndromes with isolated del (5q): determinants of response and survival in a real-world setting A Singh, A Al-Kali, JM Foran, MA Elliott, K Begna, T Badar, N Khera, ... American journal of hematology 97 (10), E377-E379, 2022 | 3 | 2022 |
| Integrating large language models in systematic reviews: a framework and case study using ROBINS-I for risk of bias assessment B Hasan, S Saadi, NS Rajjoub, M Hegazi, M Al-Kordi, F Fleti, M Farah, ... BMJ Evidence-Based Medicine, 2024 | 2 | 2024 |
| Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial … MG Abdelmagid, A Al-Kali, MR Litzow, KH Begna, WJ Hogan, MS Patnaik, ... Blood cancer journal 13 (1), 122, 2023 | 2 | 2023 |
| TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q) A Tefferi, F Fleti, O Chan, NH Al Ali, A Al‐Kali, KH Begna, JM Foran, ... British journal of haematology 204 (4), 1243-1248, 2024 | 1 | 2024 |
| Therapy-Related Myelodysplastic Syndromes with Isolated Del (5q): Comparative Analysis of Phenotype and Long-Term Survival F Fleti, A Singh, A Al-Kali, JM Foran, MA Elliott, K Begna, T Badar, ... Blood 140 (Supplement 1), 6940-6941, 2022 | | 2022 |
